The first long-term comparison of psilocybin vs an SSRI for MDD suggests the psychedelic was associated with better overall ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the ...

This study aimed to explore the association between major depressive disorder (MDD) and suicide risk in dementia patients.A cohort of 625,218 individuals aged ≥40 years with dementia between 2007 and ...

The first-in-human Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic profile of ENX-104 in ...

The AMPLIFY trial will assess the safety and efficacy of ABX-002 when used alongside existing SSRI or SNRI treatments.

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an ...

For patients with major depressive disorder (MDD), seizure duration of 60 to 69 seconds induced by electroconvulsive therapy (ECT) is associated with the highest remission rates compared with ...

Researchers applied machine learning to predict depressive symptoms, revealing sleep quality and anxiety as key factors ...

We identified 32 studies that met our inclusion criteria. Results: We found that the relative risk of developing a depressive disorder was incidence rate ratio = 0.79 (95% confidence interval ...

The lead indication for ENX-104 is the treatment of major depressive disorder (MDD) characterized by anhedonia (aMDD). Anhedonia is the inability to experience pleasure in normally pleasurable ...